FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to immunology and biotechnology. There are presented versions of C3b antibodies each of which is characterised by the presence of six CDR and does not bind C3. What is described is a pharmaceutical composition on the basis of the antibody and a set used for prevention and treatment of a complement-related disorder.
EFFECT: use of the invention provides new C3b antibodies, Fab fragment of which inhibits an alternative complement cascade with lC50 approximately 100 nM that can find application in medicine for prevention and treatment of the complement-related disorder, eg an inflammatory or degenerative disease.
29 cl, 26 dwg, 1 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PREVENTING AND TREATING COMPLEMENT-CAUSED OCULAR PATHOLOGIES | 2008 |
|
RU2522976C2 |
| APPLICATION OF COMPLEMENT PATHWAY INHIBITORS FOR TREATMENT OF EYE DISEASES | 2006 |
|
RU2417099C2 |
| AFFINITY-MATURED CRIG VERSIONS | 2009 |
|
RU2553517C2 |
| COMPOSITIONS AND METHODS OF INHIBITING MASP-1, MASP-2 AND/OR MASP-3 FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | 2013 |
|
RU2655299C2 |
| COMPOSITIONS AND METHODS OF INHIBITING MASP-1, AND/OR MASP-2, AND/OR MASP-3 FOR TREATING VARIOUS DISEASES AND DISORDERS | 2013 |
|
RU2709351C2 |
| USE OF COMPLEMENT PATHWAY INHIBITORS TO TREAT OCULAR DISEASES | 2010 |
|
RU2583927C2 |
| COMPOSITIONS FOR INHIBITION OF MASP-2-DEPENDENT COMPLEMENT ACTIVATION | 2012 |
|
RU2636038C2 |
| OPTIMIZED OPTIONS OF ANTI-VEGF ANTIBODIES | 2016 |
|
RU2763916C2 |
| METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | 2012 |
|
RU2662563C2 |
| NOVEL ANTIBODIES | 2008 |
|
RU2490277C2 |
